Table 2. Viral load responses: Abacavir versus placebo groups.
| ABC group | Placebo Group | Odds Ratio (95% CI)a |
P-valueb | |
|---|---|---|---|---|
| Week 16 | ||||
| Failure Analysisc | ||||
| Total non-failures | 102 (73%) | 99 (69%) | ||
| Total failures | 38 (27%) | 44 (31%) | 1.20 (0.69, 2.09) | 0.509 |
| Suppression status (intent to treat)d | ||||
| RNA<500 | 99 (78%) | 98 (73%) | ||
| RNA≥500 | 28 (22%) | 37 (27%) | 1.33 (0.725, 2.45) | 0.387 |
| Suppression status (on initial therapy)e | ||||
| RNA<500 | 94 (86%) | 97 (75%) | ||
| RNA≥500 | 15 (14%) | 33 (25%) |
a
ABC group is the reference group
b
Product Hypergeometric Exact Test
c
Includes all subjects in an intent-to-treat analysis, using the primary virologic failure definition for the study
d
Uses a definition of virologic failure of ≥ 500 copies/mL and includes all subjects regardless of whether they were on their originally assigned therapy
e
Uses a definition of virologic failure of ≥ 500 copies/mL and includes only subjects on their originally assigned therapy
f
Not done